MARKET

TRVN

TRVN

Trevena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.740
-0.390
-12.46%
After Hours: 2.300 -0.44 -16.06% 18:01 08/11 EDT
OPEN
2.890
PREV CLOSE
3.130
HIGH
2.920
LOW
2.650
VOLUME
24.52M
TURNOVER
--
52 WEEK HIGH
3.680
52 WEEK LOW
0.4600
MARKET CAP
293.68M
P/E (TTM)
-10.0661
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TRVN stock price target is 4.750 with a high estimate of 6.00 and a low estimate of 3.500.

EPS

TRVN News

More
Trevena Announces A Common Stock Offering; No Details Disclosed
Benzinga · 1h ago
Trevena shares are trading lower after the company announced a proposed common stock offering. No terms were disclosed.
Benzinga · 1h ago
Trevena Announces Proposed Public Offering Of Common Stock; Terms Not Disclosed
CHESTERBROOK, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous
Benzinga · 2h ago
ZI, NGL among premarket losers
Seeking Alpha - Article · 9h ago
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 9h ago
Why Trevena Stock Surged Today
Motley Fool · 23h ago
Mid-Afternoon Market Update: Dow Surges 300 Points; Omeros Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 1.09% to 27734 while the NASDAQ fell 0.45% to 10961.67. The S&P also rose, gaining 0.17% to 3,356.99.
Benzinga · 1d ago
OMER, TRVN, KODK and NAVB among midday movers
Seeking Alpha - Article · 1d ago

Industry

Biotechnology & Medical Research
-2.36%
Pharmaceuticals & Medical Research
-0.93%

Hot Stocks

Symbol
Price
%Change

About TRVN

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
More

Webull offers kinds of Trevena Inc stock information, including NASDAQ:TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.